U.S. markets closed

BioCorRx Inc. (BICX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.60000.0000 (0.00%)
At close: 2:45PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6000
Open1.6000
BidN/A x N/A
AskN/A x N/A
Day's Range1.6000 - 1.6000
52 Week Range1.3900 - 3.5000
Volume26
Avg. Volume1,760
Market Cap8.675M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-0.7040
Earnings DateNov 16, 2018 - Nov 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study
    GlobeNewswire

    BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study

    Announces Promotion of Lourdes Felix to CEO; Brady Granier to Serve as PresidentANAHEIM, CA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire ‒ BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended September 30, 2020. The Company also announced the promotion of Lourdes Felix to CEO of BioCorRx, replacing Brady Granier who will serve as President and will continue to serve as CEO of BioCorRx’s subsidiary, BioCorRx Pharmaceuticals Inc. Ms. Felix will continue in her role as CFO, and both Ms. Felix and Mr. Granier will retain their roles as members of the board of directors.“Lourdes’ vital contribution to the Company makes her the right CEO for the next chapter at BioCorRx. In our partnership over the years, she has been a key player in defining and executing on our strategic initiatives,” said Mr. Granier. “Specifically, this transition will allow her to oversee capital markets and strategic aspects of the operational business, while allowing me more time to focus on the expansion of our subsidiary, BioCorRx Pharmaceuticals Inc., where I will continue to serve as CEO, as we advance our lead candidate, BICX102, through the FDA approval process. I remain highly encouraged by the outlook for the business and look forward to continuing to work closely with Lourdes as President and fellow board member to support the growth and exciting initiatives underway at BioCorRx.”“I am grateful and honored to serve as CEO of BioCorRx and appreciate the confidence shown by Brady and the Board of Directors,” said Lourdes. “I would like to thank Brady for his outstanding leadership over the years and his tremendous contributions to BioCorRx, as he has been instrumental in expanding our R&D program under the Company’s subsidiary, BioCorRx Pharmaceuticals Inc., building strategic partnerships and expanding into new markets. I look forward to continuing to work closely with Brady and executing on the Company’s strategic vision in advancing our addiction treatment and weight loss solutions.”“Our subsidiary, BioCorRx Pharmaceuticals Inc., continues to progress our pivotal good laboratory practice (GLP) preclinical studies of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. The main GLP study began in March of this year and while limited, we have experienced some delays due to scheduling challenges on the part of the contract research organization (CRO) conducting the study. Our team is currently working on the IND application that we still strive to submit by the end of the year, however that could also happen after the new year if we experience any delays from any of the various third parties we rely on to receive data or prepare the application. Our subsidiary also continues to work on preclinical studies of VDM-001, a new molecule being developed to reverse opioid overdose. Fentanyl has become a major driving force behind the opioid epidemic in the US which continues to be exacerbated by the COVID-19 pandemic. We are very encouraged by some early preclinical data that demonstrated the ability of VDM-001 to block analgesic effects of fentanyl in vivo.”“We also recently announced that we have formed a partnership with Truusight Health, a healthcare solutions and care navigation and management company, to bring the Company’s Recovery Program to self-funded health plans. Through this partnership, plan members covered under Truusight Health programs will now have access to Beat Addiction Recovery, a medication-assisted treatment (MAT) program, which combines proprietary cognitive-behavioral therapy (CBT) and peer support, with medication prescribed by a licensed treatment provider. We are excited to expand the reach of our recovery program, which helps ensure people have access to remote treatment and recovery during this difficult time,” concluded Lourdes.About BioCorRxBioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery (formerly the BioCorRx® Recovery Program) is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx™ Weight Loss Program is also a medication assisted weight loss program; please visit www.uncraverx.com for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit www.BioCorRx.com.Safe Harbor StatementThe information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.BioCorRx Inc. investors@BioCorRx.com 714-462-4880Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 bicx@crescendo-ir.com

  • GlobeNewswire

    BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans

    ANAHEIM, CA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx®”) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders (SUD), today announced their partnership with Truusight Health, a healthcare solutions and care navigation and management company, to bring the Company’s Recovery Program to self-funded health plans. The Company is also announcing a name change to the recovery program that will become effective upon launch of the new website at www.BeatAddiction.com. The program name will change from BioCorRx® Recovery Program to Beat Addiction Recovery. The program will include more options which will be disclosed on the new website.Through this partnership, plan members covered under Truusight Health programs will now have access to Beat Addiction Recovery, a medication-assisted treatment (MAT) program, which combines proprietary cognitive-behavioral therapy (CBT) and peer support, with medication prescribed by a licensed treatment provider.“Unfortunately, people suffering from substance use disorder have limited options for comprehensive care during the pandemic as the country has been forced to stay safe at home in many regions. When you combine that with the rising number of opioid deaths we are seeing around the country, it is clear that we need to bring SUD care to as many Americans as possible,” said Brady Granier, CEO, and Director of BioCorRx, Inc. “We are proud to expand the reach of our recovery program to health plans under Truusight at a time when remote SUD care has become increasingly more important to keep people engaged.”According to an article published by NPR in August 2020, drug overdoses have spiked almost 18 percent during the coronavirus pandemic as Americans suffering from SUD are confined to their homes with limited resources for recovery. Beat Addiction Recovery’s mobile platform allows patients to get the assistance they need from the comfort of their homes. The HIPAA-compliant platform allows individuals to engage in live conversations with their doctors, behavioral counselors, therapists, peer support specialists, and others on their care team at any time via messaging, voice, or video within the mobile app.“We are working hard to change the way people view substance use and co-occurring mental health disorders and are constantly seeking innovative, cutting-edge, evidence-based solutions that improve access to and provide more options for high quality, cost-effective care,” said Jonathan Ferguson, Chief Executive Officer of Truusight Health. “Right now, we face new challenges due to COVID-19 and social distancing rules. There are even more barriers for those who are actively in treatment or seeking care. I am pleased to introduce a new and highly impactful partnership between Truusight Health and BioCorRx that helps ensure people have access to remote treatment and recovery during this difficult time.”About Truusight HealthTruusight Health is a care navigation and management company that understands addiction is a brain disease; one that is influenced by biology, social, and environmental factors.  It requires an approach to care that surrounds the person with both clinical intervention, behavioral and social supports. The company focuses on the “whole person” and consider both clinical and behavioral/social supports to be equally important in helping a person achieve recovery.  Truusight Health assists health plans by assertively and intentionally managing the services that supports each person needs to achieve life-long recovery. Managing relapses with care not criticism and a deep belief that failure is not an acceptable outcome.  Truusight Health’s integrated and coordinated system of care is aligned with experience and expertise from their internal and external care team that is tracked and managed with proven technology.About BioCorRxBioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program (Beat Addiction Recovery) is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx™ Weight Loss Program is also a medication assisted weight loss program; please visit www.uncraverx.com for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit www.BioCorRx.com.Safe Harbor StatementThe information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.BioCorRx Inc. investors@BioCorRx.com 714-462-4880Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 bicx@crescendo-ir.com

  • GlobeNewswire

    BioCorRx Provides Business Update for the Second Quarter of 2020

    ANAHEIM, CA, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2020.  Brady Granier, CEO, and Director of BioCorRx, Inc., stated, “Despite the COVID-19 pandemic, our pivotal GLP preclinical studies of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders being developed under the Company’s subsidiary, BioCorRx Pharmaceuticals Inc., continues to progress and have been uninterrupted by COVID-19 to date. The aim of the preclinical studies is to collect data in support of the safety of BICX102 in order to submit our IND application to the U.S. Food and Drug Administration. We do not anticipate much of a delay, if any, to the completion of these pivotal studies and we continue to strive to submit our IND application toward the end of the year with the goal of starting human studies in early 2021. We are dependent on our third-party partners in this matter.“As the COVID-19 global pandemic continues, so does the nation’s opioid epidemic. The full toll of restrictions and business closures due to COVID-19 likely won’t be determined for some time. The American Medical Association has stated that it ‘is greatly concerned by an increasing number of reports from national, state and local media suggesting increases in opioid-related mortality—particularly from illicitly manufactured fentanyl and fentanyl analogs.’ BioCorRx Pharmaceuticals continues to work on preclinical studies of VDM-001, a new molecule being developed to reverse opioid overdose through our partnership with VDM Biochemicals, Inc. There are a few small preclinical studies currently underway and VDM-001 may represent an effective alternative to naloxone in the overdose reversal market. Fentanyl has become a major driving force behind the opioid epidemic in the US. In 2018 alone, 31,000 people died from synthetic opioid overdoses. We are very encouraged by some early preclinical data that showed the ability of VDM-001 to block analgesic effects of fentanyl in vivo. The current studies that are currently underway will hopefully allow us to gain more insight into VDM-001 and its viability to progress to further development.” A copy of the Company’s quarterly report on Form 10-Q for the second quarter ended June 30, 2020 has been filed with the Securities and Exchange Commission and posted on the Company’s website at https://ir.biocorrx.com/.About BioCorRxBioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx™ Weight Loss Program is also a medication assisted weight loss program; please visit www.uncraverx.com for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit www.BioCorRx.com. Safe Harbor Statement The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.BioCorRx Inc. investors@BioCorRx.com 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 bicx@crescendo-ir.com